New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT05360680
First seen Jan 23, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This early-stage study tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, stomach, pancreatic, or ovarian) that had returned or spread and were no longer responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Participants received the drug by IV, and researchers monitored side effects and tumor changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Carol G. Simon Cancer Center - Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Medical Center (University Hospitals)
Cleveland, Ohio, 44106, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Johns Hopkins University
Baltimore, Maryland, 21231, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
Northwest Medical Specialties, PLLC
Tacoma, Washington, 98405, United States
-
Stanford Advanced Medicine Cancer Center
Palo Alto, California, 94304, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.